Premium
Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p‐tau
Author(s) -
Janelidze Shorena,
Palmqvist Sebastian,
Leuzy Antoine,
Stomrud Erik,
Verberk Inge M.W.,
Zetterberg Henrik,
Ashton Nicholas J.,
Pesini Pedro,
Sarasa Leticia,
Allué José Antonio,
Teunissen Charlotte E.,
Dage Jeffrey L.,
Blennow Kaj,
MattssonCarlgren Niklas,
Hansson Oskar
Publication year - 2022
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1002/alz.12395
Subject(s) - medicine , cognitive impairment , amyloid (mycology) , amyloid beta , disease , amyloid β , alzheimer's disease , pathology , oncology , psychology , gastroenterology
We studied usefulness of combining blood amyloid beta (Aβ)42/Aβ40, phosphorylated tau (p-tau)217, and neurofilament light (NfL) to detect abnormal brain Aβ deposition in different stages of early Alzheimer's disease (AD).